Immuneering Corp — Director's Dealing 2025

Jun 16, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2025-06-13

Reporting Person: KEATING LAURIE (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-06-13	Stock Option	$1.90	A	33350	Acquired	2035-06-13	Class A Common Stock (33350)	Direct

Footnotes

F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 13, 2025, and will be fully vested and exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first.